Metastatic Colorectal Cancers Completed Phase 2 Trials for Dalotuzumab (DB11840)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00614393Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)Treatment